Targeted Genotyping
After conducting whole genome analyses, researchers generally hone in on genes of interest in specific individuals. Typical fine-mapping applications include SNP analysis, loss of heterozygosity studies, and chromosome copy number studies. For these projects, Cogenics offers the following genotyping services:

• Affymetrix GeneChip® Scanner 3000 7G MegAllele System, using MIP (molecular inversion probes). MIP is an innovative assay technology that addresses the challenges of a targeted approach by offering flexible multiplexing from 1,500 to 20,000 SNPs per individual assay, the highest level of multiplexing commercially available.

• Sequenom MassARRAY® platform, for high throughput targeted genotyping. The Sequenom system is ideal when analyzing from 25 - 1,000 SNPs.

• Luminex® platform, for flexible multiplexing in the range of 1 to 100 SNPs, which meets the needs of a wide variety of applications.

• DMET Panel: Interrogates 1,700 SNPs associated with >160 drug metabolism enzyme and transport genes.

• Pain Research Panel: contains over 3000 SNPs in 350 genes whose protein products are linked to biological pathways that influence pain sensitivity and/or psychological state

Benefits of Cogenics’ targeted genotyping services include:

• Choice of Affymetrix ,Sequenom, or Luminex platform
• Choice of Affymetrix GeneChip® Mapping or MegAllele Arrays
• Most comprehensive panel of ADME assays available in GLP-compliant format
• Rapid turnaround time of 3-5 days
• High throughput capacity
• Research or GLP-compliant services

Samples
Clients are required to submit purified genomic DNA or EDTA-preserved blood for the Affymetrix platform and purified genomic DNA, EDTA-preserved blood, buccal cells, or FTA® cards for the Sequenom platform.

Results
Final Reports for Affymetrix platform assays include raw microarray images, raw microarray data files, SNP scores and genotypes for each patient sample, as well as links to public and client databases where appropriate.

Final Reports for Sequenom platform assays include SNP scores and genotypes for each patient sample, as well as links to public and client databases where appropriate. For projects utilizing HAP® Database analyses, Final Reports also identify the genes and SNPs analyzed as well as possible mechanisms underlying observed associations, variability at the protein level through secondary structure and multi-species amino acid alignment.